嵌合抗原受体-T细胞免疫治疗应用现状及相关实验室检查  

Current application of chimeric antigen receptor T cell immunotherapy and related laboratory examinations

作　　者：刘志远[1] 庞博[1] Liu Zhiyuan;Pang Bo(Guanganmen Hospital,China Academy of Chinese Medical Science,Beijing 100053,China)

机构地区：[1]中国中医科学院广安门医院检验科,北京100053

出　　处：《中华检验医学杂志》2022年第8期871-874,共4页Chinese Journal of Laboratory Medicine

摘　　要：嵌合抗原受体(CAR)T细胞免疫治疗是肿瘤治疗的一次革命,CAR-T细胞免疫治疗在B细胞白血病、淋巴瘤和多发性骨髓瘤的治疗中疗效显著,但存在抗原逃逸、抗原异质性、毒副作用等不足,在其他恶性血液肿瘤和实体肿瘤治疗中也面临诸多挑战。CAR-T细胞免疫治疗前后进行全面、持续的实验室指标检测对毒副作用的早期预警及治疗监测具有重要作用。未来需要不断改进CAR-T细胞的设计、优化治疗方案,提高其抗肿瘤活性,为肿瘤治疗带来新的突破。Chimeric antigen receptor(CAR)-T cell immunotherapy is a revolutionary advancement in cancer treatment,and is highly effective in treatment of B cell leukemia,lymphoma,and multiple myeloma.However,it has some deficiencies such as antigen escape,antigen heterogeneity,toxic and side effects,which also pose challenges for therapy of other hematological malignancies and solid tumors.Comprehensive and continuous laboratory monitoring before and after CAR-T cell immunotherapy plays an important role in early warning of toxic and side effects,as well as theraputic evaluation.In the future,new breakthroughs for tumor therapy.Should be focused on improving CAR-T cells design,enhancing their anti-tumor activity,and optimizing therapeutic regimen.

关 键 词：肿瘤 嵌合抗原受体T细胞 免疫治疗 临床实验室技术 

分 类 号：R730.51[医药卫生—肿瘤]